Hengrui's FORM 483 is not that simple | Jianzhi Research

According to the FDA website, Hengrui's January on-site inspection has entered the OAI phase, which means that the FDA is not satisfied with the company's first-stage response and corrective actions, and has made a formal regulatory decision. However, it should be emphasized that Hengrui still has the opportunity to submit rectification measures before further regulatory measures are taken. And this on-site inspection has nothing to do with the dual AI therapy going global.

wallstreetcnJun 7 00:22 ET

Report: Fosun Pharmaceuticals Considers Privatizing Hong Kong Stock Holding Subsidiary Fu Hong Han Lin

On Monday, according to media reports quoting people familiar with the matter, Fosun Pharmaceutical is considering a privatization acquisition of Fuhong Hanlin, which is listed on the Hong Kong stock market. People familiar with the matter said that Fosun Pharmaceuticals is cooperating with a consulting agency on a potential privatization offer plan, and other investors may also join the deal. Fuhong Hanlin is a holding subsidiary of Fosun Pharmaceutical. Fosun Pharmaceutical holds 53.61% of Fuhong Hanlin's total share capital. Since May 23, Fu Hong Hanlin has suspended trading on the Hong Kong Stock Exchange pending the announcement of the merger and acquisition. Negotiations are still ongoing, and it remains to be seen whether a deal will actually be reached in the future.

wallstreetcnMay 29 09:12 ET

Can I still buy money now? UBS conducted in-depth research on China's gold market

UBS pointed out that the Chinese market sentiment tends to buy when the price of gold recovers. As a result, future investors may be more likely to react flexibly to the price and be willing to buy at a decline of around $2,250 per ounce.

wallstreetcnMay 20 07:49 ET

Hengrui diet pills went overseas for 6 billion US dollars, and this time they are no longer making wedding gowns for others | Insight Research

Through an innovative transaction structure, Hengrui uses minimal risk to obtain the highest potential overseas returns, while providing shareholders with more stable returns.

wallstreetcnMay 16 20:08 ET

Why is it difficult for Fat Donglai to solve Yonghui's questions

Fat Donglai, who was once praised by Lei Jun as “the magic presence of China's retail industry,” has been a bit busy lately. Following the launch of targeted support for*ST Bugao (002251.SZ) in December of last year, Fat Donglai recently took another step to help Yonghui Supermarket (601933.SZ), a leading fresh food supermarket. As soon as news broke that the founder of Fat Donglai visited Yonghui Supermarket's Zhengzhou store on May 8, Yonghui Supermarket immediately reaped a rise and fall, increasing its market value by 2.2 billion yuan. But in reality, Fat Donglai, who set off the secondary market, is only a regional retailer in the far corner of Henan Province. Revenue just broke 10 billion dollars in 2023; Yonghui Supermarket is the industry

wallstreetcnMay 10 21:58 ET

2024 Financial Report | After breaking through 40 billion dollars in revenue, how can Huadong Pharmaceutical face the challenge of “deceleration”

Big dividends

wallstreetcnApr 18 23:33 ET